Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era
Abstract How to identify follicular lymphoma (FL) patients with low disease burden but high risk for early progression is unclear. Building on a prior study demonstrating the early transformation of FLs with high variant allele frequency (VAF) BCL2 mutations at activation-induced cytidine deaminase...
Main Authors: | Cristina Correia, Matthew J. Maurer, Samantha J. McDonough, Paula A. Schneider, Paige E. Ross, Anne J. Novak, Andrew L. Feldman, James R. Cerhan, Susan L. Slager, Thomas E. Witzig, Bruce W. Eckloff, Hu Li, Grzegorz S. Nowakowski, Scott H. Kaufmann |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2023-05-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-023-00847-1 |
Similar Items
-
Immunogenicity of COVID ‐19 vaccines in patients with follicular lymphoma receiving frontline chemoimmunotherapy
by: Lim, YJ, et al.
Published: (2024) -
Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma
by: Reid W. Merryman, et al.
Published: (2023-02-01) -
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
by: Yucai Wang, et al.
Published: (2022-01-01) -
Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era
by: Arushi Khurana, et al.
Published: (2021-07-01) -
Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy.
by: Michael P Chu, et al.
Published: (2015-01-01)